Summary
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding include cancer prevention research and cancer control investigation aimed at understanding and/or ameliorating the symptoms and toxicity related to:

- Neurocognitive function
- Gender specific symptom reduction
- Behavioral interventions
- Treatment dose alterations or delivery
- Cancer risk reduction
- Chemotherapy induced peripheral neuropathy

Integral to these priorities, are the establishment of biospecimen repositories for molecular studies and applications addressing/prioritizing health disparities, the elderly, racial and ethnic minorities, sexual and gender minorities, and rural residents.

Funding can be requested for up to $18,000 and is contingent upon NRG Oncology’s receipt of the Notice of Award from the Division of Cancer Prevention. One to two projects may be funded. Projects are to be implemented September 1, 2020 and completed by December 31, 2021. No carry over funds will be issued. An interim progress report is due within 6 months of starting the project and a completed progress report is due at the end of the project period. Applications from institutions that are able to waive indirect costs and/or provide cost sharing, while not mandatory, will be prioritized.

Background
The NRG NCORP core grant focuses on continued leadership in cancer prevention and control (CPC) research. Our CPC objectives will benefit the NCTN Program through continued research across the breadth of NRG disease sites with a unique focus in both women’s health, attributable to our gynecologic and breast cancer expertise, and technology assessment, through the world’s largest radiotherapy (RT) focused research base. CPC will design and conduct trials to assess cancer prevention, reduce the burden of cancer treatment-related symptoms across solid tumor disease sites with an emphasis on the prevention of women’s cancers, and a focus on high prevalence symptoms in our population.

Instructions for Applicants
If you have an interest in this application, please submit a 3-5-page proposal to fielde@nrgoncology.org by 5pm ET, Friday, May 1, 2020. This opportunity is open to all investigators. Proposals should include:
• Title page (not part of the page limit) that indicates the title of the proposal, the lead investigator and all co investigators to include institutional affiliations and contact information
• A description of the project, including summary of specific aims
• A detailed description of how the project will help lead to a Phase II or Phase III NCORP concept
• An outline of NRG Oncology resources requested (i.e. biospecimen materials, statistical support, etc.) Any expenses related to these resources should be outlined in the budget
• Timeline for the project [not included in the 5 page limit]
• NIH biosketch of PI [not included in the 5 page limit]
• A detailed budget [not included in the 5 page limit]

Submit applications to:
Erica Field, MPH, MHA
NCORP Administrator
fiede@nrgoncology.org
215-940-8824

Direct scientific questions to NRG NCORP PI and CPC Chairs:
Deborah Watkins Bruner, RN, PhD, FAAN
NRG NCORP PI
deborah.w.bruner@emory.edu

Lisa Kachnic, MD
NRG Associate Chair
Chair, Cancer Control
lak2187@cumc.columbia.edu

Douglas A. Levine, MD
Chair, Cancer Prevention
Douglas.Levine@nyulangone.org